MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 29, 2008; DOI: 10.1124/mol.107.044214


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.107.044214v1
73/4/1037    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gu, S.
Right arrow Articles by Heximer, S. P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gu, S.
Right arrow Articles by Heximer, S. P


Received for publication December 12, 2007.
Revised January 23, 2008.
Accepted for publication January 23, 2008.

The RGS2 gene product from a candidate hypertension allele shows decreased plasma membrane association and inhibition of Gq

Steven Gu 1, Sam Tirgari 1, Scott P Heximer 1*

1 University of Toronto

* Address correspondence to: E-mail: scott.heximer{at}utoronto.ca

Abstract

Hypertension is a leading risk factor for the development of cardiovascular disease. Data from human and animal studies suggest that RGS2, a potent inhibitor of Gq signaling, is important for blood pressure regulation. Recently, several RGS2 mutations in the Japanese population were found to be associated with hypertension. The product of one of these alleles, R44H, is mutated within the amino terminal amphipathic alpha helix domain, the region responsible for plasma membrane-targeting. The functional consequence of this mutation and its potential link to the development of hypertension, however, are not known. Here, we show that R44H is a weaker inhibitor of receptor-mediated Gq signaling than wild type RGS2. Confocal microscopy reveals that YFP-tagged R44H binds to the plasma membrane less efficiently than wild type RGS2. R44 is one of the basic residues positioned to stabilize lipid bilayer interaction of the RGS2 amphipathic helix domain. Tryptophan fluorescence and circular dichroism studies of this domain show that the R44H mutation prevents proper entrenchment of hydrophobic residues into the lipid bilayer without disrupting helix-forming capacity. Together, these data suggest that decreasing the side chain length and flexibility at R44 prevents proper lipid bilayer association and function of RGS2. Lastly, the R44H protein does not behave as a dominant negative interfering mutant. Thus, our data are consistent with the notion that a R44H missense mutation in human RGS2 produces a hypomorphic allele that may lead to altered receptor mediated Gq-inhibition and contribute to the development of hypertension in affected individuals.


Key words: Gq/11 family, G protein regulation, RGS proteins, Ca imaging


This article has been cited by other articles:


Home page
Circ. Res.Home page
R. R. Neubig
And the Winner Is ... RGS4!
Circ. Res., August 29, 2008; 103(5): 444 - 446.
[Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics